-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Deep brain stimulation (DBS) targeting the subthalamic nucleus (STN) or globus pallidus (GPi) can significantly improve the quality of life of patients with Parkinson's disease (PD)
Deep brain stimulation (DBS) targeting the subthalamic nucleus (STN) or globus pallidus (GPi) can significantly improve the quality of life of patients with Parkinson's disease (PD)
The individual level data of 1849 PD patients after DBS implantation were collected from the Australian government for a period of 15 years (2002-2016)
The individual level data of 1849 PD patients after DBS implantation were collected from the Australian government for a period of 15 years (2002-2016)
Research flow chart
Research flow chartThe results showed that the average implantation age of the patients was 62.
The results showed that the average implantation age of the patients was 62.
The research results support the development of technologies to reduce treatment risks, such as surgical navigation, miniaturization of hardware, and improved battery efficiency
Xu, SS, Malpas, CB, Bulluss, KJ, McDermott, HJ, Kalincik, T.
and Thevathasan, W.
(2021), Lesser-Known Aspects of Deep Brain Stimulation for Parkinson's Disease: Programming Sessions, Hardware Surgeries, Residential Care Admissions , and Deaths.
Neuromodulation: Technology at the Neural Interface.
https://doi.
org/10.
1111/ner.
13466
Leave a message here